Phase 1 data strongly de-risk the NEK7 franchise with broad biomarker normalization and clean safety. Key catalysts to watch: GEMINI-1 initiation (Q4 2026/Q1 2027), MRT-9347 IND (Q4 2026), and GFORCE-2/GALAXY-1 starts (H1 2027). Gout data expected H2 2027 provides first Phase 2 proof-of-concept readout.
Price Chart
Executive Summary
Monte Rosa Therapeutics reported positive Phase 1 data for MRT-8102, a NEK7-directed molecular glue degrader, showing robust NEK7 degradation (80-90%), normalization of multiple ASCVD pathogenic drivers (calprotectin -56%, S100A12 -46%, SAA -51%, hsCRP -85%, fibrinogen -28%, Lp(a) -24%), and a favorable safety profile with no SAEs and TEAE rates comparable to placebo (33% vs 30%). The company plans to initiate three Phase 2 studies (GFORCE-2 in CAD, GEMINI-1 in gout, GALAXY-1 in hidradenitis suppurativa) through H1 2027.
Key Facts
- 108 obese subjects with elevated CVD risk enrolled in GFORCE-1 Phase 1 study
- Median NEK7 degradation of approximately 80-90% across all three dose levels (5 mg, 20 mg, 40 mg QD)
- Median hsCRP reduced by 85%; 86% of subjects achieved hsCRP <2 mg/L
- Median calprotectin reduced by 56%, S100A12 by 46%, SAA by 51%, fibrinogen by 28%
- Median lipoprotein(a) reduced by 24%, comparable to PCSK9 inhibitors
- No SAEs reported; TEAE rates 33% (MRT-8102) vs 30% (placebo); no increased infection risk
- Phase 2b GFORCE-2 in CAD expected to initiate H1 2027; GEMINI-1 in gout Q4 2026/Q1 2027; GALAXY-1 in HS H1 2027
- NLRP3 risk alleles identified in ~30% of population, enabling potential precision medicine approach
Financial Impact
No financial data provided; clinical-stage biotech with no approved products or reported revenue
Risk Factors
- Phase 1 biomarker improvements may not translate to clinical outcomes in Phase 2
- GFORCE-2 requires completion of long-term preclinical toxicology studies before initiation
- Competition from IL-1/IL-6 biologics and colchicine in CAD; established SOC in gout and HS
- Clinical-stage biotech with no approved products; future capital needs for Phase 2 programs
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409833 |
| Document: glue-ex99_2.htm | 0001193125-26-409833 |
| Document: glue-ex99_1.htm | 0001193125-26-409833 |
| Document: 0001193125-26-409833-index-headers.html | 0001193125-26-409833 |
| Document: 0001193125-26-409833-index.html | 0001193125-26-409833 |
| Document: 0001193125-26-409833.txt | 0001193125-26-409833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 8-K | $11.26 | awaiting T+60 | — | $10.48 (−6.93%) |
Sep 30, 2026 26d ago | Press Release | $11.26 | awaiting T+60 | — | $10.48 (−6.93%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.48 (−33.29%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.48 (−55.37%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.48 (−56.44%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.48 (−56.71%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.48 (−56.71%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.48 (−56.69%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.48 (−52.98%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.48 (−40.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers